|
Video: What is a Stock Split?
|
|
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology therapies for the treatment of cancers with critical unmet medical need. Co.'s two clinical-stage product candidates are zilovertamab and ONCT-216. Co. is developing ONCT-216, an investigational small molecule that inhibits the ETS, or E26 Transformation Specific, family of oncoproteins, which have been shown in preclinical studies to alter gene transcription and RNA processing and lead to increased cell proliferation and invasion. In addition, Co. is developing ONCT-808, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. According to our Oncternal Therapeutics stock split history records, Oncternal Therapeutics has had 2 splits. | |
|
Oncternal Therapeutics (ONCT) has 2 splits in our Oncternal Therapeutics stock split history database. The first split for ONCT took place on June 10, 2019. This was a 1 for 7 reverse split, meaning for each 7 shares of ONCT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split. ONCT's second split took place on January 08, 2024. This was a 1 for 20 reverse split, meaning for each 20 shares of ONCT owned pre-split, the shareholder now owned 1 share. For example, a 142.857142857143 share position pre-split, became a 7.14285714285714 share position following the split.
When a company such as Oncternal Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Oncternal Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 7.14285714285714 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Oncternal Therapeutics shares, starting with a $10,000 purchase of ONCT, presented on a split-history-adjusted basis factoring in the complete Oncternal Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
04/18/2024 |
|
Start price/share: |
$198.80 |
|
End price/share: |
$8.60 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.67% |
|
Average Annual Total Return: |
-26.96% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$432.50 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
06/10/2019 | 1 for 7 | 01/08/2024 | 1 for 20 |
|
|